"Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label EDIT. Show all posts
Showing posts with label EDIT. Show all posts

Tuesday, November 17, 2026

An Alternative to an Uncertain AI Trade - medicine and, in particular, Genetics

 


Investment Note: Gene editing in focus

Why I like BEAM, CRSP and NTLA 

The Next Medical Revolution — and an Alternative to an Uncertain AI Trade

November 16, 2026 | Investment horizon: 2027–2028

A potentially historic turning point in medicine

Over the past several years, much of the investment world's attention and capital has been concentrated on artificial intelligence, semiconductors, data centres and the enormous infrastructure required to support them.

While AI will undoubtedly remain an important technological revolution, I believe another transformation is unfolding that may ultimately prove just as significant to humanity: the ability to treat, correct and potentially cure serious diseases by editing human genes.

This is no longer simply theoretical science.

Three publicly traded biotechnology companies—Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA)—are approaching important milestones that could help move genetic medicine from specialized experimental treatments toward broader commercial adoption.

Two years ago I took positions in all three, with BEAM as my principal investment, CRSP as the more commercially established complement and NTLA as the higher-risk, potentially higher-reward opportunity. I exited those positions in favor of the Ai buildout trade.  I am now considering entering positions again.

1. Beam Therapeutics (BEAM): My first choice

Beam is developing base editing, a technology designed to make precise changes to individual DNA letters without requiring the conventional double-strand DNA cuts associated with earlier CRISPR approaches.

This potentially provides a more precise way of addressing the genetic causes of disease.

On November 10, 2026, Beam announced positive pivotal results for risto-cel, its investigational sickle-cell treatment. The trial met its primary efficacy and safety endpoints, and the company expects to submit its FDA application as early as year-end 2026.

Equally important is BEAM-302, which aims to correct the underlying genetic defect responsible for alpha-1 antitrypsin deficiency, a serious inherited condition affecting the lungs and liver. Early clinical evidence suggests the treatment is producing the intended biological effects.

Beam reported approximately US$1 billion in cash and marketable securities at September 30, 2026. Its projected funding runway extends into mid-2029, including a conditional financing draw.

Why I am interested: Beam combines a potentially revolutionary technology platform with increasingly convincing clinical evidence, several development programs and sufficient financial resources to pursue major milestones.

I also believe its proprietary technology could make it an attractive strategic acquisition candidate for a larger pharmaceutical company seeking to expand into genetic medicine.

2. CRISPR Therapeutics (CRSP): The commercial validation

CRISPR Therapeutics has already achieved something that many biotechnology companies spend decades pursuing: bringing a gene-editing medicine to market.

Its CASGEVY treatment, developed with Vertex Pharmaceuticals, is approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.

CASGEVY generated approximately US$99 million in product revenue during the third quarter of 2026, representing 30% sequential growth. More than 750 patients worldwide had initiated treatment.

CRSP is also developing CTX310, an investigational in-body gene-editing treatment targeting serious lipid disorders. If successful, its applications could extend beyond rare genetic diseases into much larger cardiovascular markets.

The company reported approximately US$2.28 billion in cash and marketable securities, although part of that balance reflects convertible-debt financing.

Why I am interested: CRSP provides tangible evidence that gene-editing medicine can become a commercial business. Its substantial financial resources, expanding pipeline and relationship with Vertex strengthen the long-term investment case.

A potential acquisition by Vertex or another pharmaceutical company is conceivable, although existing partnerships may reduce the need for a full takeover.

3. Intellia Therapeutics (NTLA): The potentially historic catalyst

Intellia may be approaching one of the most consequential regulatory milestones in genetic medicine.

Its investigational lonvo-z treatment is designed to provide a one-time therapy for hereditary angioedema, a serious disorder that causes recurrent swelling attacks.

In Phase 3 testing, the treatment reduced attacks by approximately 87% compared with placebo over six months.

The FDA has accepted Intellia's application, with a target decision date of March 10, 2027.

If approved, lonvo-z could become the world's first commercially approved treatment that uses CRISPR to edit genes directly inside the human body.

That distinction is enormously important. Rather than removing cells, modifying them in a laboratory and returning them to the patient, in-body gene editing offers the prospect of simpler treatment delivery for certain diseases.

Intellia also has a strategic relationship with Regeneron Pharmaceuticals.

Why I am interested: NTLA offers the possibility of a major regulatory and commercial breakthrough within months. Its comparatively smaller market capitalization could make successful commercialization particularly meaningful to shareholders.

However, the company has experienced safety concerns in a separate gene-editing program, and FDA approval is not assured. I would therefore treat NTLA as the smallest and most speculative of the three investments.

4. Why Big Pharma could become interested

Large pharmaceutical companies face a continuing challenge: important medicines eventually lose patent protection, exposing billions of dollars in annual revenue to generic and biosimilar competition.

Acquiring innovative biotechnology companies is one way to replenish their development pipelines and obtain technologies that could underpin future generations of treatments.

Gene editing is especially attractive because it offers the possibility of treating diseases at their genetic source rather than managing symptoms indefinitely.

I see three potential reasons for acquisition interest:

  • Proprietary technology: A successful gene-editing platform could generate numerous future medicines, making the technology itself strategically valuable.

  • Clinical and regulatory validation: As treatments demonstrate efficacy and obtain approvals, some of the uncertainty facing potential acquirers diminishes.

  • Access to new markets: Successful gene-editing therapies for cardiovascular, metabolic and other widespread diseases could create much larger commercial opportunities than today's initial rare-disease applications.

Beam's base-editing platform, CRSP's approved treatment and Intellia's in-body editing capabilities each represent different strategic opportunities.

Existing relationships involving Pfizer, Eli Lilly, Vertex and Regeneron illustrate the pharmaceutical industry's interest in these technologies.

I consider Beam the most interesting potential acquisition candidate, followed by Intellia and CRISPR Therapeutics. This is a judgment about strategic attractiveness, not evidence of current acquisition discussions.

Importantly, my investment thesis does not depend on a takeover. These businesses must ultimately create value through successful medicines, commercialization and sustainable economics.

5. Why consider these investments now, amid the Nvidia controversy?

The timing of this opportunity is particularly interesting.

Nvidia's co-founder Jensen Huang resigned in November following reports concerning his personal conduct and allegations involving a suspected foreign-intelligence connection.

The controversy has raised questions about corporate governance, leadership succession and Nvidia's future strategic direction. The intelligence-related allegations remain unproven, and Nvidia has stated that it has no reason to believe company secrets were compromised.

More broadly, investors are increasingly questioning the financial structure supporting the AI infrastructure boom.

Enormous capital commitments, complex financing arrangements, circular investment relationships and uncertainty about future returns on AI spending have created concern about whether the market has become excessively dependent on a relatively small number of technology companies.

I do not believe this necessarily means the AI revolution is ending.

However, a temporary correction in AI-related equities could encourage investors to reconsider where the next major technological and commercial opportunities will emerge.

Genetic medicine offers a compelling alternative.

Unlike an AI infrastructure investment, whose immediate financial prospects may depend on continued data-centre construction and semiconductor spending, biotechnology companies can experience substantial valuation changes following successful clinical trials, FDA approvals and commercial adoption.

Their catalysts are different.

This does not make biotechnology immune to market corrections. Smaller biotechnology stocks are often highly sensitive to interest rates, liquidity and investor risk appetite. A broad technology selloff could initially drag biotechnology shares lower as well.

Nevertheless, over a two-year horizon, I believe successful genetic-medicine companies could develop investment momentum based on their own medical and commercial achievements, rather than the trajectory of AI infrastructure spending.

6. My proposed investment approach

I favour taking positions gradually rather than attempting to predict the precise bottom in any of these stocks.

Within a dedicated speculative genetic-medicine allocation, my preferred weighting would be:

CompanyAllocationInvestment role
BEAM45%Primary technology and growth position
CRSP40%Commercial validation and broader pipeline
NTLA15%Higher-risk regulatory and takeover optionality

I would initially establish partial positions and retain capital to take advantage of market weakness or additional clinical evidence.

There are meaningful risks: disappointing trial results, regulatory setbacks, unexpected safety problems, expensive commercialization, dilution and prolonged operating losses. The three companies also share substantial exposure to the same emerging field, making this a concentrated investment rather than a diversified healthcare portfolio.

7. My investment conclusion

I believe we may be approaching an important inflection point in genetic medicine.

For decades, many inherited diseases could be managed but not fundamentally corrected. Today, companies such as Beam, CRISPR Therapeutics and Intellia are demonstrating that this limitation may increasingly be overcome.

The medical implications are extraordinary, and the commercial implications could be substantial.

At the same time, uncertainty surrounding Nvidia, the financing of the AI infrastructure boom and the concentration of market capital in a handful of technology companies makes it sensible to investigate other sources of long-term growth.

My interest in BEAM, CRSP and NTLA is therefore based on three converging opportunities:

  1. The transition of gene editing from experimental science toward commercial medicine.

  2. The possibility that major pharmaceutical companies will increasingly seek to acquire or partner with developers of proprietary genetic technologies.

  3. The opportunity to diversify growth capital into a potentially transformative industry whose fundamental catalysts differ from those driving the AI infrastructure trade.

I regard BEAM as my first choice, CRSP as my second and NTLA as a smaller, higher-risk third position.

The next 24 months could prove particularly important as regulatory decisions, clinical results and commercialization provide clearer evidence of which companies will become leaders in genetic medicine.

The opportunity is substantial, but success is not assured. I would pursue these investments with a multi-year horizon, disciplined position sizing and a willingness to reassess the thesis as clinical and financial evidence develops.

The central investment proposition is simple: while markets debate the next phase of artificial intelligence, a revolution in the treatment of human disease may already be entering its commercial era.

Investment research note — November 16, 2026. This reflects a speculative investment thesis, not guaranteed returns or confirmed takeover interest.

Research supporting the note

The principal clinical and financial information comes from the companies' November 2026 disclosures: Beam's pivotal clinical results, CRISPR Therapeutics' Q3 results and Intellia's Q3 results.

Beam Therapeutics+2

For the Nvidia discussion, Reuters reports Huang's resignation and the related governance concerns, while distinguishing allegations from established wrongdoing. Reuters also identifies investor scrutiny of AI financing arrangements and Nvidia's leadership transition

Ed Note:

I would not disregard the possible takeover value of these three as their cutting edge technology develops and commercializes. Big Pharma is always on the lookout for such tasty morsels!

Thursday, August 28, 2025

BEAM Therapeutics - A simplified investor report!

 


Beam Therapeutics (NASDAQ: BEAM)

Simplified Investor Report – August 2025


1. What Beam Does

Beam is a gene-editing company that uses a next-gen technology called base editing.
Unlike traditional CRISPR, which “cuts” DNA, base editing changes single letters of DNA directly. This makes edits potentially safer and more precise.

Beam’s approach is being tested in blood diseases, liver diseases, and cancer cell therapies.


2. Current Pipeline (Key Drugs in Development)

  • BEAM-101 (Sickle Cell Disease / Beta Thalassemia)

    • Ex vivo (patient’s stem cells edited outside body).

    • Goal: Increase fetal hemoglobin to prevent sickling.

    • FDA gave RMAT designation in Aug 2025—can speed approval.

    • Competes with CRISPR Tx’s already-approved Casgevy.

  • BEAM-302 (Alpha-1 Antitrypsin Deficiency, AATD – In vivo)

    • Liver-targeted using LNPs (same delivery as mRNA vaccines).

    • First clinical proof: restored missing protein in patients. Big de-risking milestone.

  • BEAM-301 (GSD-Ia, rare metabolic disease – In vivo)

    • First patients dosed in 2025. Very rare disease but clear genetic target.

  • BEAM-201 (Allogeneic CAR-T for T-cell leukemia)

    • First multiplex-edited CAR-T (4 edits in one cell).

    • Potential for “off-the-shelf” cancer treatment.

Why this matters: 

Beam is not a “one trick pony”—it has 4 very different programs in the clinic (blood, liver, metabolic, cancer). This spreads risk.


3. How Beam Compares to Other Gene Editors

CompanyTechnologyStatusNotes
Beam (BEAM)Base editing4 clinical programs (in-vivo + ex-vivo + CAR-T)Broadest pipeline; proof of editing in humans (AATD).
CRISPR Tx (CRSP)CRISPR/Cas9First FDA-approved therapy (Casgevy)First mover, but rollout is slow & complex.
Intellia (NTLA)CRISPR/Cas9ATTR program in Phase 3Closest to an in-vivo commercial therapy.
Editas (EDIT)CRISPRHb disorders in Phase 2Smaller player; similar to CRSP but later.
Verve (VERV)Base editingLDL cholesterol lowering in Phase 1Early but strong human data.
Prime Medicine (PRME)Prime editingFirst patients dosedVery early stage, but big potential.

Takeaway: Beam sits between CRSP’s proven approval and Intellia’s Phase 3 lead, but has more breadth than most others. Verve and Prime validate the editing class, but are earlier.

Ed Note:  We like all six and are currently invested in two of these names!


4. Why Analysts & Institutions Are Bullish

  • Analysts: 12–13 Buys, targets $40–80 (2–4x upside from ~$17 today).

  • Catalysts: RMAT for BEAM-101, clinical proof in BEAM-302, first patients dosed in BEAM-301.

  • Big investors buying: ARK Invest, Vanguard, Swiss National Bank, others.

  • Upside potential: If one of Beam’s in-vivo therapies works, it could transform rare disease treatment—making Beam a takeover target for big pharma.


5. Risks to Consider

  • Still pre-revenue—cash burn is high.

  • Competes against already-approved products (Casgevy in SCD).

  • In-vivo gene editing is very new—long-term safety still being proven.

  • Stock is volatile and heavily tied to trial readouts.


6. Bottom Line for Retail Investors

Beam is a high-risk, high-reward biotech.

  • It has a broad and diverse pipeline (blood, liver, rare metabolic disease, CAR-T).

  • Analysts see 2–4x upside in the next 12–24 months.

  • Beam is not yet proven commercially, but recent trial wins (esp. BEAM-302) show that base editing works in humans.

  • For investors who can tolerate volatility, Beam is one of the most exciting gene-editing plays—but it should be sized carefully in a portfolio.

Ed Note:  We are long BEAM NTLA CRSP EDIT



Sunday, July 28, 2024

Here are five future technology stocks trading near their all time lows. Are they buying opportunities? Only time will tell!

 


To provide an informed perspective on these stocks (STEM, DNA, PLUG, EDIT, AEVA), let's analyze each company based on their technology innovation, market position, and merger possibilities.

1. STEM, Inc. (STEM)

  • Technology Innovation: STEM focuses on energy storage solutions and AI-driven energy management. Their Athena platform is a leader in smart energy storage and optimization.
  • Market Position: With increasing global emphasis on renewable energy and grid stability, STEM is well-positioned to capitalize on the transition to a more sustainable energy system.
  • Merger Possibilities: STEM could be an attractive acquisition target for larger energy companies looking to enhance their smart grid and energy storage capabilities.

2. Ginkgo Bioworks (DNA)


Technology Innovation: Ginkgo Bioworks is a leader in synthetic biology, offering cell programming services across various industries, including agriculture, pharmaceuticals, and industrial biotechnology.

  • Market Position: As a pioneer in synthetic biology, Ginkgo has a strong position, with partnerships and collaborations enhancing its market reach.
  • Merger Possibilities: Ginkgo's technology platform makes it a potential target for large pharmaceutical or biotechnology companies aiming to integrate advanced synthetic biology capabilities.

3. Plug Power Inc. (PLUG)

  • Technology Innovation: Plug Power specializes in hydrogen fuel cell solutions, which are critical for the future of clean energy and decarbonization efforts, particularly in transportation and industrial applications.
  • Market Position: Plug Power is a market leader in hydrogen fuel cell technology and has significant partnerships, including those with major automotive and logistics companies.
  • Merger Possibilities: Given the global push towards green hydrogen, Plug Power could be a strategic acquisition for energy giants or automotive companies aiming to bolster their clean energy portfolios.

4. Editas Medicine, Inc. (EDIT)

  • Technology Innovation: Editas Medicine is a prominent player in gene editing, leveraging CRISPR technology to develop therapies for genetic diseases.
  • Market Position: Editas holds a strong intellectual property portfolio and is advancing several clinical programs, positioning itself well in the competitive gene-editing landscape.
  • Merger Possibilities: The biopharmaceutical industry is ripe for consolidation, and Editas could attract interest from larger pharmaceutical companies seeking to expand their gene therapy pipelines.

5. Aeva Technologies, Inc. (AEVA)

  • Technology Innovation: Aeva develops next-generation sensing technology, including 4D LiDAR, which is crucial for autonomous driving and advanced driver-assistance systems (ADAS).
  • Market Position: Aeva's innovative technology and strategic partnerships with automotive OEMs position it well in the burgeoning autonomous vehicle market.
  • Merger Possibilities: Aeva could be an attractive acquisition target for automotive giants or technology companies looking to strengthen their autonomous driving capabilities.

Investment Expectations

  • Technology Innovation: All these companies are leaders or strong contenders in their respective fields, driven by cutting-edge technology.
  • Market Position: Each company has a unique market position that leverages their technological strengths, with strong growth potential in their industries.
  • Merger Possibilities: The potential for mergers and acquisitions is significant, given their innovative technologies and strategic importance to larger players in their sectors.

Conclusion

Investing in these stocks could be promising, given their strong technological foundations and market positions. However, it's essential to consider the volatility and inherent risks associated with high-tech and biotech companies. Diversifying investments and staying informed about industry trends and company developments will be crucial for managing risk and maximizing potential returns.

Among the companies mentioned, here are the ones currently trading near their all-time lows:

1. Ginkgo Bioworks (DNA)

  • Current Price: Approximately $0.30
  • Historical Context: This price is significantly close to its 52-week low of $0.26, indicating it is trading near its all-time low levels​ (MarketBeat)​.

2. Editas Medicine (EDIT)

  • Current Price: Approximately $5.65
  • Historical Context: Editas has seen substantial declines, and its current trading price is near its all-time lows, reflecting a significant drop from previous higher levels​ (Stock Analysis)​.

3. Aeva Technologies (AEVA)

  • Current Price: Approximately $3.66
  • Historical Context: Aeva's current price is close to its all-time lows, especially considering the company's recent performance and stock price history​ (Stock Analysis)​.

Analysis and Expectations

  • DNA (Ginkgo Bioworks): Trading near its all-time low suggests potential for significant upside if the company can leverage its synthetic biology platform for commercial success and partnerships.

  • EDIT (Editas Medicine): Being near its all-time low could present a buying opportunity, especially if their gene-editing therapies progress successfully through clinical trials.




  • AEVA (Aeva Technologies): Close to all-time low, reflecting market skepticism, but their 4D LiDAR technology could be a game-changer if autonomous driving and ADAS markets grow.


Given the current trading levels, investing in these stocks could be seen as high-risk, high-reward.

These low prices might be appealing for long-term investors who believe in the underlying technologies and market positions of these companies. However, it's crucial to stay informed about ongoing developments and market conditions that could affect these stocks.

Discl: we are long four of these stocks!

Related Articles:

Here are ten small-cap, publicly traded companies that are incorporating cutting-edge AI technology into healthcare!



Sunday, July 7, 2024

Editas Medicine $EDIT has pioneered the use of CRISPR technology to develop innovative genomic medicines, potentially transforming the treatment of a wide range of genetic diseases

 


Editas Medicine is a viable player in the biotech field due to several factors:

  1. Technological Advancements:

    • Editas focuses on CRISPR-Cas9 and CRISPR-Cas12a (Cpf1) gene editing technologies, which are at the forefront of genetic engineering and therapeutic development. These technologies allow for precise, targeted modifications to the genome, opening the door to treatments for a variety of genetic diseases​ (Editas Medicine)​​ (Editas Medicine)​.
  2. Pipeline and Clinical Trials:

    • Editas has a diverse pipeline with multiple programs in various stages of development. Notably, their BRILLIANCE trial for treating Leber congenital amaurosis (LCA10), a rare genetic eye disorder, has shown promising results. The success of this and other trials will be critical for their future viability​ (markets.businessinsider.com)​​ (SciTechDaily)​.


  3. Strategic Focus:

    • The company's focus on both in vivo (within the body) and ex vivo (outside the body) gene editing expands its potential applications. This dual approach enables them to target a wide range of diseases and patient populations, increasing their market potential​ (Editas Medicine)​​ (markets.businessinsider.com)​.
  4. Partnerships and Collaborations:

    • Collaborations with other biotech firms and research institutions bolster their research capabilities and expand their technological reach. Partnerships are essential for sharing expertise, resources, and accelerating development timelines​ (markets.businessinsider.com)​.
  5. Financial Position:

    • While the company has experienced fluctuations in stock prices, ongoing support from investors and strategic financial management are vital. Recent buy ratings from analysts indicate a positive outlook based on the company's strategic focus and upcoming clinical data​ (markets.businessinsider.com)​.
  6. Regulatory and Market Challenges:

    • Like all biotech firms, Editas faces regulatory hurdles and market competition. Successful navigation of these challenges will be essential for their continued viability. Positive trial outcomes and regulatory approvals will be critical milestones​ (markets.businessinsider.com)​​ (SciTechDaily)​.

In summary, Editas Medicine's focus on cutting-edge CRISPR technology, a robust and diverse pipeline, strategic collaborations, and positive analyst ratings support its viability going forward. However, their success will hinge on the continued advancement of their clinical programs, regulatory approvals, and the ability to maintain financial stability.

The founders of Editas Medicine are notable scientists with significant contributions to the field of gene editing:

  1. Feng Zhang:

    • Feng Zhang is a prominent figure in the development of CRISPR technology. He is a core member of the Broad Institute of MIT and Harvard and has been instrumental in advancing the use of CRISPR-Cas9 for genome editing in mammalian cells. His work has been widely recognized and has earned him numerous awards, including the prestigious Canada Gairdner International Award​ (Editas Medicine)​​ (SciTechDaily)​.
  2. Jennifer A. Doudna:


    • Jennifer Doudna is a professor of chemistry and molecular and cell biology at the University of California, Berkeley. She is a co-recipient of the Nobel Prize in Chemistry in 2020 for her role in the development of CRISPR-Cas9, alongside Emmanuelle Charpentier. Her research has been pivotal in the field of gene editing, and she has received many other accolades, including the Breakthrough Prize in Life Sciences​ (Editas Medicine)​​ (SciTechDaily)​.
  3. George Church:

    • George Church is a professor of genetics at Harvard Medical School and a professor of health sciences and technology at Harvard and MIT. He has made significant contributions to various biotechnological fields, including the Human Genome Project. Church is known for his pioneering work in the development of genome sequencing and editing technologies​ (Editas Medicine)​​ (SciTechDaily)​.
  4. J. Keith Joung:

    • J. Keith Joung is a pathologist and molecular biologist at Massachusetts General Hospital and Harvard Medical School. He is recognized for his contributions to the development of gene editing technologies, including zinc-finger nucleases and CRISPR-Cas systems. Joung's work has significantly impacted the field of genome editing and its applications in medicine​ (Editas Medicine)​.
  5. David R. Liu:

    • David Liu is a professor at Harvard University and a member of the Broad Institute. He has developed several innovative technologies in the field of gene editing, including base editing and prime editing. Liu's research aims to create more precise and efficient methods for editing DNA, with the potential for wide-ranging therapeutic applications​ (Editas Medicine)​​ (SciTechDaily)​.

These founders have played critical roles in the development and advancement of gene editing technologies, making Editas Medicine a leading company in the biotech industry.

The top five institutional investors in Editas Medicine, Inc. are:

  1. Vanguard Group Inc. - Holds approximately 8.46 million shares.
  2. BlackRock Inc. - Owns about 7.84 million shares.
  3. Deep Track Capital, LP - Holds around 5.47 million shares.
  4. State Street Corp - Owns approximately 5.07 million shares.
  5. SPDR S&P Biotech ETF - Holds around 3.18 million shares​ (Fintel - Financial Intelligence)​​ (Stock Analysis)​.

These institutions collectively own a significant portion of the company's shares,

 reflecting strong institutional interest in Editas Medicine.

"The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field" says the author Dr. Kasi



Tuesday, May 21, 2024

Investor John Templeton got his start in penny stocks. Here are some large companies that were once pennystocks!

Let’s explore how some of these tech giants 

and other companies were once penny stocks:



  1. Apple (NASDAQ: AAPL): Apple, founded in 1976, had its ups and downs. With nine stock splits taken into account, it was in penny stock territory as recently as 1995. Now, it trades above $300 a share1.
  1. Ford Motor Company (NYSE: F): Ford, a Fortune 500 company, was also once a penny stock. It has come a long way since then2.
  1. Amazon (NASDAQ: AMZN): Believe it or not, Amazon was once a penny stock too. Its remarkable growth turned it into the e-commerce giant we know today3.
  1. Google (now Alphabet): Google (now part of Alphabet) started as a penny stock when it went public in 2004. Its search engine dominance and expansion into various tech sectors transformed it into a powerhouse1.
  1. Microsoft (NASDAQ: MSFT): Microsoft, with its stock splits considered, was in penny stock territory until the mid-1990s. It has since become one of the world’s most valuable companies1.

These transformations demonstrate the potential for substantial growth

even from humble beginnings!


As an interesting side note, in 1998 when Amazon was still in it's infancy, Jeff Bezos was not a multi billionaire. 

However, he saw a company that he believed had a vision for the future.  He invested $250,000 (a large sum for him at the time) into that company. That company was Google!

Bezos turned that modest $250,000 investment into $7.9 billion 

a 3 million percent-plus return



Here are five more companies that were once penny stocks that have achieved significant success:


  1. Sirius XM Holdings Inc. (SIRI): Sirius XM, one of the world’s biggest audio and communication companies, was once a penny stock trading at only $0.60 about 10 years ago. It has since grown over 965% and expanded its reach with the addition of Pandora Radio1.
  1. Accelerate Diagnostics Inc. (AXDX): Focused on solving antibiotic resistance challenges, Accelerate Diagnostics has seen substantial growth. Its stock was once considered a very small penny stock but has risen significantly since then1.

Remember, investing in penny stocks can be risky, but these examples show that with the right catalysts and timing, substantial growth is possible! 


Are there hidden gems in today's crop of penny stocks with new technology?

We currently own shares in these Microcap companies!

: 

DNA RXRX IONQ QBTS OUST AEVA WONDR CHPT ADPT OPEN EDIT CRSP STEM PLUG